VAV1 and chronic myelomonocytic leukemia: Unlike mice engrafted with Vav-creTet2fl/flTp53fl/fl cells, mice receiving Vav-cre Tet2fl/fl or Vav-cre Tp53fl/fl donor cells had longer survival times and died from a chronic myelomonocytic leukemia–like disease (for Vav-cre Tet2fl/fl mice) or T cell malignancies (for Vav-cre Tp53fl/fl mice) (Figure 4D).